Subversion of diabetes treatment! The world's first glucagon receptor antibody clinical data released
June 20, 2017 Source: Drug Research and Development
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];From June 9th to 13th, local time, the 77th Annual Meeting of the American Diabetes Association (ADA) Science was held in San Diego. The five-day conference attracted more than 16,000 professionals in diabetes from multiple countries around the world. It is reported that the annual meeting is divided into eight major themes of acute and chronic complications, islet biology/insulin secretion, including 380 oral reports and 2228 posters.
1The world's first glucagon receptor antibody clinical data released
In the "ADA Presidents Oral Presentation" session of the General Assembly, REMD Biotherapeutics and its subsidiary Beijing Kexin Meide, the Chinese scientist Dr. Yan Hai, jointly announced the world's first glucagon receptor antibody REMD-477. Phase I clinical trial data for the treatment of type 1 diabetes.
The results of the trial showed that patients with type 1 diabetes who received a single injection of REMD-477 not only significantly reduced insulin consumption, but also reduced their blood glucose levels without complications of hypoglycemia.
Specifically, a randomized, double-blind, placebo-controlled trial enrolled 21 adults with type 1 diabetes (8 men, 13 women). The patient was measured the baseline value of daily insulin dosage and blood glucose level on the first day of admission observation. On day 2, 10 patients received a single dose of 70 mg of REMD-477 subcutaneously, and the remaining 11 patients received a placebo injection.
Comparing daily insulin usage and blood glucose levels, it was found that patients treated with a single dose of REMD-477 had a 26% reduction in daily insulin use during hospitalization compared with patients receiving placebo. In addition, patients in the REMD-477 treatment group had an average daily glucose level of 20-31 mg/dL lower than those in the placebo group within 3 weeks after discharge, and did not increase hypoglycemia.
2 The hypothesis of being "cold" was finally confirmed
The regulation of blood glucose concentration in normal people is mainly achieved by the mutual restriction of insulin and glucagon at multiple levels. Insulin produced by islet β cells promotes the absorption of blood sugar, thereby lowering blood glucose concentration; and glucagon produced by islet α cells synthesizes endogenous blood glucose through the liver to raise blood sugar.
The lack of islet beta cells and the inability to produce insulin are major features of type 1 diabetes. Without the restriction of insulin, the secretion of glucagon is not effectively inhibited, which in turn causes a large amount of synthesis of endogenous blood glucose, which eventually leads to hyperglycemia. Before insulin can be used to treat type 1 diabetes, the patient's fat and protein are converted to endogenous blood sugar through activation of the pancreatic hyperglycemia pathway, and eventually the patient will die in childhood due to extreme weight loss.
At present, the treatment of type 1 diabetes mainly depends on insulin injection, there is no cure, and it cannot be effectively prevented. The industry has also been looking for other therapies that are more effective in treating and even curing type 1 diabetes.
More than 40 years ago, Roger H. Unger, a member of the American Academy of Sciences and a tenured professor of Southwestern Medical College in Texas, based on years of preclinical animal model research and clinical observations, found that all types of diabetes have a common feature, namely, the body's pancreas is high. An increase in blood glucose. In 1975, he and Professor Lelio Orci of the Swiss Institute of Histology and Embryology proposed a hypothesis in the Lancet that interferes with the mechanism by which glucagon raises blood sugar, lowers and blocks endogenous glycemic production, and lowers blood sugar. The concentration eventually reaches the goal of treating diabetes.
This hypothesis is a very small faction in the environment of insulin alone's treatment of diabetes. In addition, there is no effective drug for this experiment to verify this hypothesis, so it has not been popular.
REMD-477 is the world's first antibody drug candidate to block the over-activated glucagon pathway based on this "cold" hypothesis. Jeremy Pettus, an assistant researcher in the above-mentioned clinical trial and assistant professor of endocrinology at the University of California, San Diego, said: "Our research strongly confirms that long-term blocking of the glucagon pathway can improve blood sugar and lower insulin dose, thus greatly improving 1 The theory of type 2 diabetes treatment. At the same time, the study also found that REMD-477 treatment avoids the occurrence of hypoglycemia. This is a difficult problem to be overcome in the treatment of type 1 diabetes."
Dr. Yan Hai said: "The discovery and application of insulin partially solved the problem of hyperglycemia, but it brought about the complications of hypoglycemia caused by drugs. At the same time, the application of insulin did not really solve the endogenous mediated by glucagon. The problem of blood glucose synthesis. The discovery of REMD-477 has effectively controlled the excessive synthesis of endogenous blood glucose."
According to reports, REMD Biotherapeutics is planning a follow-up study to study the safety, efficacy and pharmacokinetics of REMD-477 after multiple treatments in approximately 75 type 1 diabetic volunteers. In time, Beijing Kexin Meide will also cooperate with Jiuzhitang in clinical trials of REMD-477 for the treatment of type 1 diabetes and type 2 diabetes in China.
End
References: 1) Updates from Our 77th Scientific Sessions
2) Glucagon-Blocking Drug Reduces Need for Insulin and Improves Blood Glucose Levels for Patients with Type 1 Diabetes
Erythritol For Chewing Gum,Erythritol Reddit,Pyure Erythritol,Swerve Confectioners Sugar Substitute
Ningxia Eppen Biotec CO.,LTD , https://www.nxeppen.com